These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1843446)

  • 1. Clinical trials in Alzheimer's disease. A report from the Medical Research Council Alzheimer's Disease Clinical Trials Committee.
    Swash M; Brooks DN; Day NE; Frith CD; Levy R; Warlow CP
    J Neurol Neurosurg Psychiatry; 1991 Feb; 54(2):178-81. PubMed ID: 1843446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials.
    Mohs RC
    Genes Brain Behav; 2005 Apr; 4(3):129-33. PubMed ID: 15810901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A neuropsychological test battery for use in Alzheimer disease clinical trials.
    Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
    Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical global impressions in Alzheimer's clinical trials.
    Schneider LS; Olin JT
    Int Psychogeriatr; 1996; 8(2):277-88; discussion 288-90. PubMed ID: 8994897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dementia and Alzheimer's disease. Indications, diagnosis, and treatment.
    Golden R
    Minn Med; 1995 Jan; 78(1):25-9. PubMed ID: 7877576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.
    Gauthier S; Ferris S
    Int J Clin Pract Suppl; 2001 May; (120):29-39. PubMed ID: 11406924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
    McLendon BM; Doraiswamy PM
    J Geriatr Psychiatry Neurol; 1999; 12(1):39-48. PubMed ID: 10447153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales.
    Oremus M; Perrault A; Demers L; Wolfson C
    J Geriatr Psychiatry Neurol; 2000; 13(4):197-205. PubMed ID: 11128059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.
    Mohs RC; Knopman D; Petersen RC; Ferris SH; Ernesto C; Grundman M; Sano M; Bieliauskas L; Geldmacher D; Clark C; Thal LJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S13-21. PubMed ID: 9236948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADCS Prevention Instrument Project: overview and initial results.
    Ferris SH; Aisen PS; Cummings J; Galasko D; Salmon DP; Schneider L; Sano M; Whitehouse PJ; Edland S; Thal LJ;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S109-23. PubMed ID: 17135805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Memory: therapeutic approach. Clinical evaluation].
    Pasquier F
    Therapie; 2000; 55(4):513-9. PubMed ID: 11098729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of behavior and mood scales.
    Perrault A; Oremus M; Demers L; Vida S; Wolfson C
    J Geriatr Psychiatry Neurol; 2000; 13(4):181-96. PubMed ID: 11128058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor structure and reliability of the Alzheimer's Disease Assessment Scale in a multicenter trial with linopirdine.
    Kim YS; Nibbelink DW; Overall JE
    J Geriatr Psychiatry Neurol; 1994; 7(2):74-83. PubMed ID: 8204192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales.
    Demers L; Oremus M; Perrault A; Champoux N; Wolfson C
    J Geriatr Psychiatry Neurol; 2000; 13(4):170-80. PubMed ID: 11128057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scales as outcome measures for Alzheimer's disease.
    Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
    Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.
    Cano SJ; Posner HB; Moline ML; Hurt SW; Swartz J; Hsu T; Hobart JC
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1363-8. PubMed ID: 20881017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.